[HTML][HTML] The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for …
KR Cooke, L Luznik, S Sarantopoulos, FT Hakim… - Biology of Blood and …, 2017 - Elsevier
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
Age-associated changes in human hematopoietic stem cells
WW Pang, SL Schrier, IL Weissman - Seminars in hematology, 2017 - Elsevier
Aging has a broad impact on the function of the human hematopoietic system. This review
will focus primarily on the effect of aging on the human hematopoietic stem cell (HSC) …
will focus primarily on the effect of aging on the human hematopoietic stem cell (HSC) …
Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
Donor selection contributes to improve clinical outcomes of T-cell–replete haploidentical
stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy). The …
stem cell transplantation (haplo-SCT) with posttransplant cyclophosphamide (PT-Cy). The …
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care
VE Kennedy, RL Olin - The Lancet Haematology, 2021 - thelancet.com
Haematopoietic stem-cell transplantation (HSCT) has seen substantial growth among older
adults. Chronological age is no longer viewed as an absolute barrier to HSCT, and …
adults. Chronological age is no longer viewed as an absolute barrier to HSCT, and …
Current progress in NK cell biology and NK cell-based cancer immunotherapy
R Tarazona, N Lopez-Sejas, B Guerrero… - Cancer Immunology …, 2020 - Springer
A better understanding of the complex interactions between the immune system and tumour
cells from different origins has opened the possibility to design novel procedures of …
cells from different origins has opened the possibility to design novel procedures of …
[HTML][HTML] Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical …
MP Pereira, M Remberger, C Chen, A Gerbitz… - … and Cellular Therapy, 2023 - Elsevier
The choice between an older matched sibling donor (MSD) and a younger matched
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …
unrelated donor (MUD) in allogeneic hematopoietic cell transplantation (HCT) remains a …
Senotherapeutics for mesenchymal stem cell senescence and rejuvenation
PF Wong, M Dharmani, TS Ramasamy - Drug Discovery Today, 2023 - Elsevier
Highlights•MSC senescence poses a major challenge in regenerative application.•
Senotherapeutics could overcome MSC senescence during in vitro expansion.• …
Senotherapeutics could overcome MSC senescence during in vitro expansion.• …
Young (< 35 years) haploidentical versus old (≥ 35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant …
We compared transplantation (HSCT) outcomes in AML patients undergoing HSCT with post-
transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (< 35 …
transplant cyclophosphamide (PTCy) in first complete remission from 1065 young (< 35 …
High graft CD8 cell dose predicts improved survival and enables better donor selection in allogeneic stem-cell transplantation with reduced-intensity conditioning
R Reshef, AP Huffman, A Gao, MR Luskin… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To characterize the impact of graft T-cell composition on outcomes of reduced-
intensity conditioned (RIC) allogeneic hematopoietic stem-cell transplantation (alloHSCT) in …
intensity conditioned (RIC) allogeneic hematopoietic stem-cell transplantation (alloHSCT) in …
Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
C Niederwieser, E Morozova, L Zubarovskaya… - Bone Marrow …, 2021 - nature.com
Allogeneic hematopoietic stem-cell transplantation (HSCT) remains the only curative option
for patients with advanced chronic myeloid leukemia (CML). However, outcome is dismal …
for patients with advanced chronic myeloid leukemia (CML). However, outcome is dismal …